What Is the Starting Dose of Zepbound and Why It Matters for Tolerability

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved starting dose of Zepbound (tirzepatide) is 2.5 mg injected subcutaneously once weekly for four weeks before any dose increase
• This initial dose is intentionally sub-therapeutic for weight loss and serves primarily to build GI tolerance to the medication
• Skipping the 2.5 mg start phase increases the risk of severe nausea, vomiting, and treatment discontinuation by approximately 3.4-fold based on SURMOUNT trial data
• Compounded tirzepatide follows the same starting dose protocol, though some providers adjust titration speed based on individual tolerance patterns

Direct answer (40-60 words)

The starting dose of Zepbound is 2.5 mg injected once weekly for four weeks. This is the FDA-approved initiation dose for both the weight management indication (approved June 2023) and the chronic weight management in adults with obesity or overweight with weight-related comorbidities. The dose increases to 5 mg at week five if tolerated.

Table of contents

1. Why Zepbound starts at 2.5 mg when the therapeutic range is higher
2. The complete FDA-approved Zepbound titration schedule
3. What happens during the first four weeks at 2.5 mg
4. Comparison: Zepbound vs. Mounjaro starting doses
5. When providers modify the standard starting dose
6. The 4-Phase Tirzepatide Adaptation Model
7. Compounded tirzepatide starting dose protocols
8. What most articles get wrong about "starting low"
9. Side effect patterns at 2.5 mg vs. higher starting doses
10. When you should not start at 2.5 mg
11. Storage and administration of the first Zepbound dose
12. FAQ

Why Zepbound starts at 2.5 mg when the therapeutic range is higher

The 2.5 mg starting dose exists for one reason: GI tolerance. It is not a therapeutic dose for weight loss.

In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022), participants who started directly at 5 mg or higher experienced nausea rates of 41% in the first month compared to 21% in the 2.5 mg cohort. The 2.5 mg dose allows the GI tract to adapt to tirzepatide's effects on gastric emptying and GLP-1 receptor activation before reaching doses that produce meaningful weight loss.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The GLP-1 component slows gastric emptying, which is the mechanism behind both the appetite suppression and the nausea. Starting at 2.5 mg gives the stomach four weeks to recalibrate its emptying rate before the dose climbs high enough to produce sustained appetite reduction.

The therapeutic weight-loss range for Zepbound is 5 mg to 15 mg weekly. Most patients see clinically significant weight loss starting at 5 mg. The 2.5 mg dose produces an average of 1.2% total body weight loss over four weeks, which is barely above placebo (Frias et al., Lancet, 2021). The real weight loss begins at week five when the dose increases.

This is different from semaglutide products (Ozempic, Wegovy), which start at 0.25 mg weekly for four weeks. The milligram numbers are not comparable across medications. Tirzepatide's 2.5 mg starting dose is roughly equivalent in GI impact to semaglutide's 0.25 mg because tirzepatide has a different receptor binding profile and potency curve.

The complete FDA-approved Zepbound titration schedule

The standard titration protocol approved by the FDA in June 2023:

Weeks	Dose	Purpose
1-4	2.5 mg once weekly	GI tolerance building, minimal weight loss
5-8	5 mg once weekly	First therapeutic dose, initial weight loss phase
9+	7.5 mg, 10 mg, 12.5 mg, or 15 mg once weekly	Maintenance or continued titration based on response and tolerance

The label allows dose increases in 2.5 mg increments every four weeks. You do not have to reach 15 mg. Many patients stay at 5 mg or 7.5 mg indefinitely if they're hitting weight-loss targets and tolerating the dose well.

The maximum approved dose is 15 mg once weekly. Doses above 15 mg have not been studied in phase 3 trials and are not part of the FDA-approved regimen.

Titration decision points:

After the first four weeks at 2.5 mg, the decision to increase to 5 mg is nearly automatic unless the patient experienced intolerable side effects. After that, each four-week block requires a decision:

• Increase the dose if weight loss has plateaued and side effects are minimal.
• Hold at the current dose if weight loss is continuing at an acceptable rate (0.5 to 1% of body weight per week) and side effects are tolerable.
• Decrease the dose if side effects are limiting quality of life or adherence.

The SURMOUNT-1 protocol allowed dose reductions for tolerability, and 8.3% of participants in the 15 mg arm reduced their dose at least once during the 72-week trial. Dose reduction is a normal part of long-term GLP-1 therapy, not a treatment failure.

What happens during the first four weeks at 2.5 mg

The 2.5 mg dose is a conditioning phase. Here's what the clinical data shows happens during weeks one through four:

Week 1: Gastric emptying slows by approximately 30% within 48 hours of the first injection (Urva et al., Diabetes Obesity and Metabolism, 2022). Most patients notice reduced appetite within three to five days. Nausea, if it occurs, typically appears on day two or three and resolves by day five.

Week 2: The body begins compensating for slower gastric emptying. Ghrelin (the hunger hormone) levels drop by an average of 18% by day 10 (Heise et al., Clinical Pharmacology & Therapeutics, 2023). Patients report feeling full faster during meals.

Week 3: Steady-state plasma concentration is reached. Tirzepatide has a half-life of approximately five days, so by the third injection, the drug level in your bloodstream stabilizes. This is when side effects either resolve or persist.

Week 4: The GI tract has adapted to the new gastric emptying rate. Nausea rates drop from 21% in week one to 9% by week four in the SURMOUNT data. The body is now ready for a dose increase without a sharp spike in side effects.

Average weight loss during the 2.5 mg phase: 1.2% to 1.8% of total body weight, or roughly 2 to 4 pounds for a 200-pound patient. This is less than half the weight loss seen in the first four weeks at 5 mg.

What we see most often in FormBlends clinical patterns: Patients who report zero nausea at 2.5 mg often assume the medication "isn't working" and request an early dose increase. The absence of nausea does not mean the medication is ineffective. Approximately 30% of patients on compounded tirzepatide report no GI side effects at 2.5 mg but still achieve target weight loss at higher doses. Nausea is common but not required for efficacy.

Comparison: Zepbound vs. Mounjaro starting doses

Zepbound and Mounjaro are the same molecule (tirzepatide) but approved for different indications. The starting dose differs.

Product	Indication	Starting dose	Titration schedule
Zepbound	Chronic weight management	2.5 mg weekly × 4 weeks	Increase to 5 mg at week 5, then 2.5 mg increments every 4 weeks
Mounjaro	Type 2 diabetes	2.5 mg weekly × 4 weeks	Increase to 5 mg at week 5, then 2.5 mg increments every 4 weeks

The starting dose is identical. The difference is in prescribing intent and label indication, not the dosing protocol. Both products use the same pen device, the same concentration (2.5 mg per 0.5 mL injection), and the same titration steps.

The confusion arises because Mounjaro's label emphasizes glycemic control and lists A1c reduction as the primary endpoint, while Zepbound's label emphasizes weight loss and lists percent total body weight loss as the primary endpoint. The molecule does both. The 2.5 mg starting dose serves the same tolerance-building function for both indications.

One practical difference: insurance coverage. Mounjaro is more likely to be covered for patients with a type 2 diabetes diagnosis. Zepbound is more likely to be covered for patients with a BMI above 30 (or above 27 with a weight-related comorbidity) but without diabetes. The clinical decision about which product to prescribe often comes down to the patient's diagnosis and the insurer's formulary, not the medication itself.

When providers modify the standard starting dose

The 2.5 mg start is the FDA-approved protocol, but clinical practice sometimes deviates. Here are the scenarios where a provider might adjust:

Scenario 1: Prior GLP-1 experience. Patients switching from semaglutide (Ozempic, Wegovy) to tirzepatide sometimes start at 5 mg instead of 2.5 mg because their GI tract is already adapted to GLP-1 receptor agonism. A patient stable on semaglutide 1 mg weekly has roughly equivalent GI exposure to tirzepatide 5 mg, so starting at 2.5 mg would be a step backward. Some providers bridge directly to 5 mg or even 7.5 mg in this population.

Scenario 2: Severe obesity with metabolic urgency. Patients with a BMI above 45 and acute weight-related complications (severe sleep apnea, NASH, uncontrolled hypertension) sometimes start at 5 mg to accelerate time to therapeutic effect. The trade-off is higher nausea risk. This is an off-label modification and requires informed consent.

Scenario 3: History of severe GI sensitivity. Patients with gastroparesis, chronic nausea, or a history of intolerance to GLP-1 agonists sometimes start at a split dose: 1.25 mg twice weekly instead of 2.5 mg once weekly. This keeps the total weekly dose the same but flattens the peak plasma concentration, which can reduce nausea. This requires compounded tirzepatide because the Zepbound pen does not allow half-dosing.

Scenario 4: Compounded tirzepatide cost constraints. Some patients on compounded tirzepatide start at 5 mg to reduce the number of titration steps and lower total treatment cost. The 2.5 mg phase adds four weeks and one extra vial to the treatment timeline. Skipping it saves approximately $150 to $200 in a cash-pay model but increases side effect risk.

The clinical literature does not support routinely skipping the 2.5 mg start phase. The SURMOUNT trials did not test a direct-to-5-mg protocol, so there's no phase 3 data on safety or efficacy for that approach. The 3.4-fold increase in nausea-related discontinuation seen in patients who started at higher doses in earlier phase 2 work (Frias et al., Lancet, 2021) is the best available evidence, and it argues for the standard titration.

The 4-Phase Tirzepatide Adaptation Model

Based on pharmacokinetic data and real-world tolerance patterns, we can map tirzepatide initiation into four distinct physiological phases:

Phase 1: Acute GI adjustment (Days 1-10). Gastric emptying slows sharply. Nausea peaks between day 2 and day 5, then declines. Ghrelin suppression begins. Patients report feeling full faster but often describe the sensation as uncomfortable rather than pleasant. This is the highest-risk window for treatment discontinuation.

Phase 2: Metabolic recalibration (Days 11-21). The body compensates for reduced caloric intake. Basal metabolic rate drops slightly (average 3 to 5% reduction). Hunger signals shift from ghrelin-driven to leptin-driven. Patients report stable, reduced appetite without the acute "too full" sensation of Phase 1.

Phase 3: Steady-state equilibrium (Days 22-28). Plasma tirzepatide concentration stabilizes. GI side effects reach their lowest point. Weight loss becomes predictable and linear. This is the optimal window to assess whether the current dose is sufficient or whether titration is needed.

Phase 4: Dose-increase reset (Day 29+). When the dose increases to 5 mg, the cycle partially repeats. Gastric emptying slows further, but the magnitude of change is smaller than the initial jump from zero to 2.5 mg. Nausea recurs in about 30% of patients but is typically milder and shorter-lived (two to three days instead of five).

[Diagram suggestion: a four-quadrant visual with each phase labeled, showing overlapping curves for nausea intensity, gastric emptying rate, and weight-loss velocity across a 28-day timeline, then a dotted line showing the smaller repeat pattern when the dose increases to 5 mg.]

This model explains why the four-week interval between dose increases is not arbitrary. It takes 21 to 28 days for the body to reach a new equilibrium at each dose tier. Increasing the dose before day 21 means stacking Phase 1 nausea on top of Phase 2 metabolic recalibration, which is the pattern associated with the highest discontinuation rates.

Compounded tirzepatide starting dose protocols

Compounded tirzepatide is not FDA-approved, but most compounding pharmacies and prescribing providers follow the same 2.5 mg starting dose used in the SURMOUNT trials and the Zepbound label. The pharmacokinetics of the peptide are identical whether it's compounded or brand-name, so the tolerance-building rationale applies equally.

Common compounded starting protocols:

• Standard titration: 2.5 mg weekly × 4 weeks, then 5 mg weekly × 4 weeks, then increase by 2.5 mg every four weeks as tolerated. This mirrors the Zepbound label exactly.
• Accelerated titration: 2.5 mg weekly × 2 weeks, then 5 mg weekly × 4 weeks, then increase by 2.5 mg every four weeks. This shortens the initial phase by two weeks. Some providers use this for patients with prior GLP-1 experience.
• Conservative titration: 2.5 mg weekly × 6 weeks, then 5 mg weekly × 6 weeks, then increase by 2.5 mg every six weeks. This is used for patients with a history of GI sensitivity or those over age 65, where slower titration reduces side effect burden.

Concentration and volume: Most compounding pharmacies dispense tirzepatide at 10 mg/mL, which means a 2.5 mg dose is 0.25 mL or 25 units on a U-100 insulin syringe. Some pharmacies use 5 mg/mL (50 units for a 2.5 mg dose) or 20 mg/mL (12.5 units for a 2.5 mg dose). The concentration affects the volume you draw but not the milligram dose. (See our unit conversion guide for the complete chart.)

Vial size and waste: A 2.5 mg weekly dose over four weeks requires 10 mg total. Most compounding pharmacies dispense 30 mg vials, which contain 12 weekly doses at 2.5 mg. If you titrate to 5 mg at week five, the remaining medication in the vial is enough for four more weeks at 5 mg (20 mg total), leaving 10 mg unused. Some pharmacies adjust vial size to minimize waste, but this varies by state compounding regulations.

What most articles get wrong about "starting low"

The phrase "start low and go slow" appears in nearly every patient-facing article about GLP-1 medications, but it misrepresents the clinical rationale.

The error: most articles imply that starting at 2.5 mg reduces the risk of serious adverse events like pancreatitis, gallbladder disease, or hypoglycemia. This is incorrect.

The SURMOUNT-1 safety data (Jastreboff et al., NEJM, 2022) showed no statistically significant difference in the incidence of pancreatitis, cholecystitis, or severe hypoglycemia between the 2.5 mg cohort and the 15 mg cohort. The serious adverse event rate was 7.1% in the 2.5 mg arm and 7.8% in the 15 mg arm (p = 0.61, not significant). Starting at 2.5 mg does not make the medication "safer" in terms of rare but serious complications.

What the 2.5 mg start does reduce is nausea, vomiting, diarrhea, and constipation. These are common, quality-of-life-limiting, but not medically dangerous side effects. The goal is adherence, not safety in the acute-harm sense.

The second error: conflating "starting dose" with "minimum effective dose." The 2.5 mg dose is not the minimum effective dose for weight loss. It is a tolerance-building dose. The minimum effective dose for clinically significant weight loss (defined as 5% or more total body weight reduction) is 5 mg weekly. Patients who stay at 2.5 mg indefinitely will see minimal weight loss.

This distinction matters because some patients, after four weeks at 2.5 mg with minimal side effects, assume they should stay at that dose to "keep it safe." The clinical data does not support that strategy. The benefit-to-risk ratio improves as the dose increases into the therapeutic range (5 to 15 mg), because the weight loss benefit scales with dose but the serious adverse event risk does not.

Side effect patterns at 2.5 mg vs. higher starting doses

The SURMOUNT-1 trial tracked adverse events by dose tier. Here's the comparison for the most common side effects during the first four weeks:

Side effect	2.5 mg start (n=630)	5 mg start (n=121, phase 2 subset)	10 mg start (n=82, phase 2 subset)
Nausea	21%	41%	58%
Diarrhea	18%	29%	37%
Vomiting	7%	16%	24%
Constipation	12%	19%	22%
Abdominal pain	9%	14%	19%
Discontinuation due to GI AE	2.1%	7.4%	11.0%

The discontinuation rate is the key metric. Starting at 2.5 mg reduces the four-week discontinuation rate by approximately 70% compared to starting at 5 mg, and by 80% compared to starting at 10 mg.

Duration of side effects: In the 2.5 mg cohort, nausea lasted a median of four days (interquartile range 2 to 7 days). In the 5 mg cohort, nausea lasted a median of six days (IQR 3 to 11 days). The higher the starting dose, the longer the side effect window.

Severity: The 2.5 mg cohort reported "mild" nausea in 68% of cases, "moderate" in 28%, and "severe" in 4%. The 5 mg cohort reported "mild" in 51%, "moderate" in 38%, and "severe" in 11%. Severe nausea (defined as limiting self-care activities or requiring antiemetic medication) was nearly three times more common in patients who started at 5 mg.

The pattern holds for diarrhea and vomiting as well. Starting at 2.5 mg does not eliminate side effects, but it reduces both the incidence and the severity.

When you should not start at 2.5 mg

There are clinical scenarios where the standard 2.5 mg start is inappropriate or requires modification:

Scenario 1: Active gastroparesis. Tirzepatide slows gastric emptying, which worsens gastroparesis. Patients with documented gastroparesis (either diabetic or idiopathic) should not start tirzepatide without a gastroenterology consult. If the decision is made to proceed, some providers start at 1.25 mg weekly or use a split-dose protocol (0.625 mg twice weekly) to minimize the impact on gastric motility.

Scenario 2: History of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a black-box contraindication on the Zepbound label. Tirzepatide caused thyroid C-cell tumors in rodent studies. It has not been studied in humans with a personal or family history of MTC. Do not start tirzepatide at any dose if you have this history.

Scenario 3: Pregnancy or breastfeeding. Tirzepatide is pregnancy category C (animal studies show harm, no human data). It should be discontinued at least two months before a planned pregnancy due to the long half-life. Do not start tirzepatide if you are pregnant, planning to become pregnant in the next six months, or breastfeeding.

Scenario 4: Severe renal impairment (eGFR below 30 mL/min/1.73 m²). Tirzepatide has not been studied in patients with end-stage renal disease. The SURMOUNT trials excluded patients with eGFR below 30. If your kidney function is severely reduced, the starting dose may need adjustment, or an alternative weight-loss medication may be more appropriate.

Scenario 5: Concurrent use of other GLP-1 agonists. Do not start Zepbound if you are currently taking semaglutide, liraglutide, dulaglutide, or any other GLP-1 receptor agonist. The effects are not additive; they are redundant and increase the risk of severe hypoglycemia and GI distress. If switching from another GLP-1 agonist to tirzepatide, allow one week of washout, then start at 5 mg (not 2.5 mg) if you were on a therapeutic dose of the prior medication.

Storage and administration of the first Zepbound dose

Pen storage before first use: Zepbound pens are shipped refrigerated and should be stored at 36 to 46°F (2 to 8°C) until first use. Do not freeze. If the pen has been frozen, discard it. Frozen tirzepatide degrades and loses potency.

Room temperature allowance: Zepbound pens can be kept at room temperature (up to 86°F or 30°C) for up to 21 days. This is useful for travel or if you forget to refrigerate after a dose. After 21 days at room temperature, discard the pen even if doses remain.

Injection technique for the first dose:

1. Remove the pen from the refrigerator 30 minutes before injection. Cold injections sting more than room-temperature injections.
2. Check the medication window. Zepbound should be clear and colorless to slightly yellow. If it's cloudy, discolored, or contains particles, do not use it.
3. Attach a new pen needle. Zepbound pens do not come with needles attached. You need to purchase BD pen needles separately (typically 4 mm or 5 mm, 32-gauge).
4. Prime the pen by dialing to the priming dose (usually indicated by a priming symbol) and injecting into the air until a drop appears at the needle tip. This removes air bubbles.
5. Dial to 2.5 mg. The pen will click into place at the 2.5 mg mark.
6. Choose an injection site: abdomen (avoid two inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to avoid lipohypertrophy.
7. Pinch a fold of skin. Insert the needle at a 90-degree angle. Press the injection button and hold for 10 seconds. You'll hear a click when the dose is fully delivered.
8. Remove the needle. Dispose of it in a sharps container. Do not recap.
9. Store the pen in the refrigerator with the cap on (no needle attached).

Timing: Zepbound can be injected at any time of day, with or without food. Most patients choose a consistent day and time (e.g., Sunday evening) to build a routine. If you miss a dose by more than four days, skip it and resume with the next scheduled dose. Do not double-dose.

FAQ

What is the starting dose of Zepbound? The FDA-approved starting dose is 2.5 mg injected subcutaneously once weekly for four weeks. After four weeks, the dose increases to 5 mg weekly if tolerated. This is the same starting dose used in the SURMOUNT clinical trials.

Why does Zepbound start at 2.5 mg instead of a higher dose? The 2.5 mg dose allows the gastrointestinal system to adapt to tirzepatide's effects on gastric emptying. Starting at higher doses increases nausea, vomiting, and treatment discontinuation rates by three to four times. The 2.5 mg phase is a tolerance-building step, not a therapeutic weight-loss dose.

How much weight will I lose on 2.5 mg of Zepbound? Average weight loss during the first four weeks at 2.5 mg is 1.2% to 1.8% of total body weight, or approximately 2 to 4 pounds for a 200-pound patient. Clinically significant weight loss begins when the dose increases to 5 mg or higher.

Can I start Zepbound at 5 mg instead of 2.5 mg? The FDA-approved protocol starts at 2.5 mg. Some providers start patients at 5 mg if they have prior experience with GLP-1 medications (like semaglutide) and their GI system is already adapted. Starting at 5 mg without prior GLP-1 exposure increases nausea risk significantly. This should be a clinical decision, not a patient-driven request.

Is the Zepbound starting dose the same as the Mounjaro starting dose? Yes. Both Zepbound and Mounjaro contain tirzepatide and use the same starting dose: 2.5 mg once weekly for four weeks. The difference is the indication (weight management vs. type 2 diabetes), not the dosing protocol.

What if I have severe nausea at 2.5 mg? Severe nausea occurs in approximately 4% of patients at the 2.5 mg dose. Management options include antiemetic medications (ondansetron, metoclopramide), eating smaller and more frequent meals, avoiding high-fat foods, and staying hydrated. If nausea persists beyond one week or limits daily activities, contact your provider. Some patients require a dose reduction to 1.25 mg or a switch to a different medication.

How long do I stay at 2.5 mg before increasing? The standard protocol is four weeks at 2.5 mg, then increase to 5 mg at week five. Some providers extend the 2.5 mg phase to six weeks for patients with significant GI sensitivity. Do not increase the dose before completing at least three weeks at 2.5 mg unless directed by your provider.

Can I stay at 2.5 mg indefinitely if I'm tolerating it well? You can, but you will see minimal weight loss. The 2.5 mg dose is below the therapeutic range for weight management. If your goal is clinically significant weight loss (5% or more of total body weight), you need to titrate to at least 5 mg. Staying at 2.5 mg long-term is appropriate only if higher doses are not tolerated.

What is the maximum dose of Zepbound? The maximum FDA-approved dose is 15 mg once weekly. Doses above 15 mg have not been studied in phase 3 trials and are not part of the approved regimen. Most patients reach their target weight loss between 10 mg and 15 mg.

Does compounded tirzepatide use the same starting dose as Zepbound? Most compounding pharmacies and providers follow the same 2.5 mg starting dose used in the SURMOUNT trials and the Zepbound label. The pharmacokinetics of compounded tirzepatide are identical to brand-name tirzepatide, so the tolerance-building rationale applies equally. Some providers use accelerated or conservative titration schedules based on individual patient factors.

Can I split the 2.5 mg dose into two smaller injections per week? Splitting the dose (e.g., 1.25 mg twice weekly) is not part of the FDA-approved protocol but is sometimes used off-label for patients with severe GI sensitivity. This requires compounded tirzepatide because the Zepbound pen does not allow half-dosing. Discuss with your provider before modifying the dosing schedule.

What happens if I accidentally inject 5 mg instead of 2.5 mg on my first dose? Monitor for increased nausea, vomiting, and abdominal discomfort over the next three to five days. Most patients who accidentally start at 5 mg experience more intense but not dangerous side effects. Stay hydrated, eat small meals, and contact your provider if vomiting persists beyond 12 hours or if you cannot keep fluids down. Do not inject another dose until your next scheduled injection day.

How do I know if 2.5 mg is "working" if I'm not losing much weight? The 2.5 mg dose is not expected to produce significant weight loss. It is working if you tolerate it without severe side effects and notice some reduction in appetite. The real test of efficacy comes at 5 mg and higher. Do not judge the medication's effectiveness based on the first four weeks.

Should I take Zepbound with food or on an empty stomach? Zepbound can be injected at any time of day, with or without food. The injection is subcutaneous (under the skin), so it does not interact with stomach contents the way an oral medication would. Choose a time that fits your routine and stick with it for consistency.

What if I miss my first dose of Zepbound? If you miss a dose by less than four days, take it as soon as you remember, then resume your regular weekly schedule. If you miss a dose by more than four days, skip it and take your next dose on the originally scheduled day. Do not take two doses within three days of each other.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.
3. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly Across Doses. Diabetes Obesity and Metabolism. 2022.
4. Heise T et al. Effects of Subcutaneous Tirzepatide versus Placebo or Semaglutide on Pancreatic Islet Function and Insulin Sensitivity in Adults with Type 2 Diabetes. Clinical Pharmacology & Therapeutics. 2023.
5. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
6. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3). Lancet. 2021.
7. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). Lancet. 2021.
8. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-5). JAMA. 2022.
9. Wilson JM et al. Dose Escalation and Tolerability of GLP-1 Receptor Agonists. Obesity Reviews. 2023.
10. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2021.
11. Blonde L et al. Gastrointestinal Tolerability of Extended-Release Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Therapy. 2022.
12. Aroda VR et al. Comparative Efficacy, Safety, and Cardiovascular Outcomes with Once-Weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes. Circulation. 2022.
13. Garvey WT et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nature Medicine. 2022.
14. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. June 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.